FBXW7 R465H
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FBXW7
Variant R465H
Impact List missense
Protein Effect loss of function
Gene Variant Descriptions FBXW7 R465H (corresponds to R385H in isoform 2) lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). R465H confers a loss of FBXW7-substrate interaction and impairs substrate degradation by FBXW7, resulting in sustained NICD and MYC expression (PMID: 17646409) and also has impaired degradation of Klf5 (PMID: 28963353).
Associated Drug Resistance
Category Variants Paths

FBXW7 mutant FBXW7 inact mut FBXW7 R465H

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001349798.2
gDNA chr4:g.152328232C>T
cDNA c.1394G>A
Protein p.R465H
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_011532085.2 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_024454122.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532084.2 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_024454123.2 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_047415897.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
NM_033632 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532084.3 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
NM_001349798.2 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_024454123.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_017008362 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_024454121.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532083 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532085.3 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532084 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_047415900.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_024454124.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
NM_001349798.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
NM_033632.3 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_011532085 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
NM_033632.3 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_047415899.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_047415898.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38
XM_047415901.1 chr4:g.152328232C>T c.1394G>A p.R465H RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 inact mut hematologic cancer sensitive Entinostat Preclinical Actionable In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor sensitive Entinostat Preclinical Actionable In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor sensitive Belinostat Preclinical Actionable In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut hematologic cancer sensitive REC-2282 Preclinical Actionable In a preclinical study, REC-2282 (AR-42) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut hematologic cancer sensitive Belinostat Preclinical Actionable In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor resistant Docetaxel Preclinical Actionable In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor sensitive REC-2282 Preclinical Actionable In a preclinical study, REC-2282 (AR-42) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut breast cancer sensitive Sirolimus Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170). 18787170
FBXW7 inact mut endometrial cancer predicted - sensitive RP-3500 + RP-6306 Phase I Actionable In a Phase I trial (MYTHIC), treatment with the combination of RP-6306 and RP-3500 in ovarian or endometrial cancer patients harboring CCNE1 amplification, FBXW7 mutations, and/or PPP2R1A mutations resulted in a clinical benefit rate (CBR) of 79%, a median progression-free survival (mPFS) of 21 weeks, and a response rate of 38% in ovarian cancer (n=24), and a CBR of 48%, mPFS of 17 weeks, and a response rate of 26% in endometrial cancer (n=27) (Cancer Res (2025) 85 (8_Supplement_2): CT262; NCT04855656). detail...
FBXW7 mutant Her2-receptor negative breast cancer predicted - sensitive LY3039478 Case Reports/Case Series Actionable In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). 30060061